By Dr. Alexandra Bleicher, MD
Endocrinology Contributor, WeightLossPills.com
Table of Contents
When tirzepatide first crossed my desk as a weight-management option, I had already spent two decades managing patients whose obesity was inseparable from their metabolic disease — hypothyroidism, polycystic ovary syndrome, insulin resistance that had calcified into full type 2 diabetes over years of failed interventions. I expected the drug to perform roughly the way semaglutide had: meaningful but modest in many patients, dramatic in a few, and accompanied by the usual GI complaints that made the first eight weeks feel like a negotiation.
What I have actually seen with Zepbound is something that has genuinely changed how I think about the pharmacological ceiling for obesity treatment. The magnitude of weight loss in a substantial portion of my patients has exceeded what I would have predicted from the trial data alone — not because I doubted the trials, but because trial populations and real clinic populations are rarely identical. My patients tend to be older, carry more comorbidities, and have often been through at least one prior GLP-1 cycle. Yet the results have been striking.
The patients who have exceeded my expectations most consistently are women in their late forties and early fifties — perimenopausal or recently postmenopausal — who had previously found semaglutide underwhelming. The dual agonism that distinguishes tirzepatide from earlier GLP-1 agents appears to do something metabolically different in this cohort, and I think it has to do with the GIP receptor pathway’s role in adipose tissue. I cannot prove that from my own patient panel, but when a 51-year-old with a twelve-year history of obesity and normal thyroid function loses 19 percent of her body weight in seven months after losing only 6 percent on semaglutide over the same timeframe, that is a signal worth noting.
On the other end of the spectrum, I have had male patients with class III obesity and significant insulin resistance who responded more slowly — losing weight steadily but not dramatically — and who required more active management around the dose escalation schedule. These patients are not failures; their trajectory tends to continue downward over a longer arc. But it has reinforced for me that body composition, baseline insulin sensitivity, and the hormonal environment all interact with this drug in ways we are still working out.
The standard escalation protocol — moving up in 2.5 mg increments every four weeks — is a reasonable framework, but I treat it as a starting point rather than a mandate. In my practice, I routinely extend the time at lower doses for patients who are losing weight comfortably and tolerating the medication well. There is no compelling clinical reason to push a patient to 10 mg if they are seeing excellent results at 7.5 mg with minimal side effects. The question I am trying to answer at each visit is not ‘are we at the target dose?’ but ‘is this patient getting what they need at the current dose?’
For patients with significant nausea at dose transitions, I have had good results with a modified schedule that slows the escalation to every six or eight weeks. I also counsel patients extensively before the first injection about appetite suppression — specifically, I tell them the loss of hunger cues can feel disorienting, almost alarming, and that they need to eat on a schedule during the early weeks even when they have no desire to. Patients who are not prepared for this tend to undereat in ways that accelerate muscle loss, which then makes their long-term metabolic situation worse.
Weight-loss plateaus on tirzepatide are real and they are psychologically difficult for patients who have been experiencing consistent weekly losses. When a patient calls my office frustrated that the scale has not moved in three weeks, the first thing I do is reframe what plateau actually means in context. I pull up their labs. I look at what has happened to their fasting insulin, their HOMA-IR calculation, their triglycerides. In many cases, the scale is holding still while significant metabolic remodeling is still occurring — liver enzymes are normalizing, lipid panels are improving, visceral adipose tissue is redistributing in ways that do not show up on a bathroom scale.
That said, some plateaus are true physiologic stalls, and when I see one in a patient who has not yet reached a dose that provided adequate satiety signaling, I will consider moving up. The distinction matters. A plateau at 10 mg in someone who is eating appropriately and exercising is a different clinical situation from a plateau at 5 mg in someone who is still experiencing moderate hunger and has headroom left in the escalation schedule.
Weight is the metric patients care most about, and I understand why. But in my clinical practice, the numbers I follow most closely are not on the scale. I check fasting insulin and glucose at baseline and at three-month intervals — not just HbA1c, which tells me a ninety-day average but can obscure early improvements in postprandial glucose handling. I track ALT and AST because a meaningful percentage of my obese patients have underlying non-alcoholic fatty liver disease, and the hepatic response to significant weight loss on tirzepatide has been one of the more gratifying things to document. I have seen ALT values that were in the 70s and 80s at baseline drop into the normal range within five months.
Lipid profiles shift in interesting ways. Triglycerides tend to fall early and substantially, often within the first eight to twelve weeks. LDL changes are more variable — I see modest decreases in most patients, but the composition of LDL particles appears to shift favorably in ways that standard panels do not fully capture. I do not order advanced lipid testing routinely, but in patients where cardiovascular risk stratification matters, it has informed my thinking.
I also track blood pressure and, in patients who were previously on antihypertensive medications, I watch carefully for the need to down-titrate. I have had to reduce or discontinue antihypertensive therapy in several patients over the past year — which is a genuinely good problem to have, but one that requires active monitoring.
The most important conversation I have with patients before starting tirzepatide is about duration of treatment. Obesity is a chronic disease. The evidence on what happens when patients discontinue GLP-1 and GIP receptor agonists is consistent: weight regain occurs, and metabolic markers follow. I am not in the habit of prescribing this medication with an implicit endpoint of ‘until you reach goal weight.’ I frame it as a long-term treatment, in the same category as antihypertensives or statins — medications that manage a chronic condition and that need to continue as long as the condition exists.
That conversation changes the patient’s relationship with the medication. It shifts the goal from a destination to a process. Patients who understand they are not going to ‘finish’ the drug and then go back to their previous eating patterns tend to do the concurrent behavioral work more seriously — because they understand the medication is managing appetite, not replacing the need to develop a sustainable relationship with food over time.
I am also thinking about combination strategies as patients age and their metabolic profiles evolve. Some of my patients on tirzepatide have thyroid disease that required adjustment of levothyroxine dosing as their weight changed. The intersection of thyroid function and weight metabolism is something I monitor closely — even modest changes in body weight can affect the distribution volume for thyroid hormone and shift a previously well-controlled patient slightly out of range.
What this medication has changed most fundamentally in my practice is the ceiling I place on what’s achievable for patients with significant obesity and metabolic disease. I have stopped assuming that a patient’s history of failed interventions predicts what will happen now. The biology is different, the mechanism is different, and in patient after patient, I am seeing outcomes that have genuinely surprised me — in the best possible way.
Dr. Alexandra Bleicher, MD, is a board-certified endocrinologist and contributor at WeightLossPills.com, where she writes on metabolic medicine, GLP-1 therapy, and the intersection of thyroid and weight management.
Leave a Reply